Holen Sie sich die Stockscreener-App
848.24
1.77%
-13.81
Schlusskurs vom Vortag:
$862.05
Offen:
$858.345
24-Stunden-Volumen:
59,243
Relative Volume:
0.17
Marktkapitalisierung:
$52.15B
Einnahmen:
$3.06B
Nettoeinkommen (Verlust:
$1.28B
KGV:
43.12
EPS:
19.6719
Netto-Cashflow:
$447.35M
1W Leistung:
-4.80%
1M Leistung:
-7.81%
6M Leistung:
+57.42%
1J Leistung:
+35.66%
1-Tages-Spanne:
$845.54
$861.34
1-Wochen-Bereich:
$827.52
$887.60
52-Wochen-Spanne:
$510.06
$934.62
Argen X Se Adr Stock (ARGX) Company Profile
Vergleichen Sie ARGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
847.00 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.67 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.26 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.37 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
166.12 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | Fortgesetzt | Truist | Buy |
| 2025-09-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-08-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-05-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2025-01-17 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-11-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Strong Buy |
| 2024-10-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-08-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-07-25 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-07-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-06-15 | Eingeleitet | Societe Generale | Sell |
| 2023-05-31 | Eingeleitet | UBS | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | Eingeleitet | William Blair | Outperform |
| 2022-10-12 | Eingeleitet | Oppenheimer | Perform |
| 2022-07-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | Fortgesetzt | Stifel | Buy |
| 2022-05-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-23 | Hochstufung | Redburn | Neutral → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | Eingeleitet | Deutsche Bank | Hold |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-18 | Eingeleitet | UBS | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | Eingeleitet | Redburn | Neutral |
| 2021-03-05 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-02-10 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-10-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-27 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-09-16 | Fortgesetzt | Cowen | Outperform |
| 2019-06-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-18 | Fortgesetzt | SunTrust | Buy |
| 2019-01-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-12-17 | Eingeleitet | Goldman | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-06-29 | Eingeleitet | Nomura | Buy |
| 2018-04-09 | Eingeleitet | SunTrust | Buy |
| 2018-01-29 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Argen X Se Adr Aktie (ARGX) Neueste Nachrichten
BofA Securities raises argenx stock price target to $1,006 on strong Vyvgart outlook - Investing.com
Baird downgrades argenx stock rating to Neutral on valuation concerns - Investing.com
Argenx stock price target raised to $925 from $860 at RBC Capital - Investing.com
Argenx stock rating maintained at Buy by BofA despite TED trial failure - Investing.com South Africa
Jefferies maintains Buy rating on argenx stock despite failed TED trial - Investing.com
argenx stock rating reiterated at Buy by Guggenheim despite TED study halt - Investing.com South Africa
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Sahm
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
argenx stock tumbles after discontinuing thyroid eye disease studies - Investing.com
Stifel raises argenx stock price target to $1,248 on Vyvgart dominance By Investing.com - Investing.com South Africa
Stifel raises argenx stock price target to $1,248 on Vyvgart dominance - Investing.com India
Argenx price target raised to $910 from $800 at UBS on Vyvgart growth By Investing.com - Investing.com South Africa
Argenx price target raised to $910 from $800 at UBS on Vyvgart growth - Investing.com India
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Argenx NV ADR stock hits all-time high at $934.62 - Investing.com India
Argenx NV ADR stock hits all-time high at $934.62 By Investing.com - Investing.com South Africa
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today - Sahm
ClearBridge International Growth ADR ESG Portfolios Q3 2025 Commentary - Seeking Alpha
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Oppenheimer raises argenx stock price target to $1,040 on higher Vyvgart sales By Investing.com - Investing.com South Africa
Oppenheimer raises argenx stock price target to $1,040 on higher Vyvgart sales - Investing.com India
Quant Ratings Updated on 141 Stocks - InvestorPlace
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
argenx Announces Results of Extraordinary General Meeting of Shareholders - Sahm
Argenx stock reaches all-time high at 915.55 USD By Investing.com - Investing.com Nigeria
Argenx stock reaches all-time high at 915.55 USD - Investing.com
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN
Argenx NV ADR stock hits all-time high of 855.68 USD - Investing.com Nigeria
Argenx NV ADR stock hits all-time high of 855.68 USD By Investing.com - Investing.com South Africa
Janus Henderson Global Life Sciences Fund Q3 2025 Commentary - Seeking Alpha
argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada - Barchart.com
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View - Finviz
Piper Sandler raises argenx stock price target to $930 on strong Vyvgart sales By Investing.com - Investing.com South Africa
Piper Sandler raises argenx stock price target to $930 on strong Vyvgart sales - Investing.com
Vyvgart Fuels Strong Growth for Argenx and Supports Developing Pipeline - Morningstar
argenx SE stock price target raised to $1,146 from $800 at TD Cowen By Investing.com - Investing.com South Africa
argenx SE stock price target raised to $1,146 from $800 at TD Cowen - Investing.com India
Finanzdaten der Argen X Se Adr-Aktie (ARGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
17.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):